Crizotinib hydrochloride是一种口服生物可用的，具有选择性的 ATP 竞争性双 ALK 和 c-Met 抑制剂； 在细胞的实验中，Crizotinib hydrochloride抑制 NPM-ALK 的酪氨酸磷酸化和 c-Met 的酪氨酸磷酸化； Crizotinib hydrochloride是 ROS 原癌基因 1 (ROS1) 抑制剂；具有有效的肿瘤生长抑制作用。 Information Crizotinib hydrochloride Crizotinib (PF-02341066) hydrochloride (Xalkori) inhibits tyrosine phosphorylation of c-Met and nucleophosmin (NPM)- anaplastic lymphoma kinase (ALK) with IC50 of of 11 nM and 24 nM in cell-based assays, respectively. Crizotinib hydrochloride is also a potent ROS1 inhibitor with Ki less than 0.025 nM. Crizotinib induces autophagy through inhibition of the STAT3 pathway in multiple lung cancer cell lines. Targets ROS1 (Cell-free assay); c-Met (Cell-based assay); NPM-ALK (Cell-based assay)